Navigation Links
CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
Date:10/17/2008

ns to incorporate a number of features in the study design intended to manage the issues that can confound antidepressant clinical trial results."

Depression clinical trial expert Dr. Norman Rosenthal, Medical Director of Capital Clinical Associates and one of the lead investigators of the Tyrima Phase II study noted, "The CeNeRx team gets high marks for designing a first-class clinical trial. Recent efforts to test new antidepressants have encountered technical difficulties, such as a high placebo effect, which the current trial works hard to avoid. I am optimistic that the present trial should enable us to assess the potential of Tyrima as a potentially valuable new antidepressant agent."

Similar to the mechanism of conventional monoamine oxidase A inhibitors (MAOI), the triple-action mechanism of Tyrima elevates the levels of three key neurotransmitters (serotonin, norepinephrine and dopamine) that positively affect mood and anxiety, compared to the one or two neurotransmitters addressed by most current antidepressant drugs. This triple-action mechanism has the potential to provide improved antidepressant efficacy in some patients, while the selectivity and reversibility of Tyrima are expected to reduce or eliminate the risk of food-associated cardiovascular side effects of conventional MAOIs.

"A substantial subset of patients suffering from depression responds much better to treatment with MAOIs than other therapies, yet the risk of food-associated cardiovascular side effects of conventional MAOIs have greatly restricted their use, to the disadvantage of our patients," said Dr. Alexander Bodkin, a Tyrima Phase II investigator and Director of the Clinical Psychopharmacology Research Program at McLean Hospital of Harvard Medical School. "A novel agent such as Tyrima with proven MAOI activity in the CNS and a good safety and tolerability profile would be a valuable option for the many patients whose depression is refractory to treatment with cu
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
2. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
3. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
6. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
7. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
8. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation ... its CytoSorb® blood purification technology to help fight ... in 28 countries worldwide, today announced the appointment ... MD, FACS, as its Senior Vice President of ... Dr. Di Russo is an ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2
... China, March 23, 2011 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, ... or "the Company"), specializing in developing and producing botanical ... additives, today announced the appointment of Ms. Amy Xue ... "We are truly delighted that Ms. Xue will be ...
... March 23, 2011 Dr. Michael Hayden, a Xenon ... Gairdner Wightman Award for leadership in medical science in ... honour for Dr. Hayden, having previously been awarded the ... Canadian Institutes of Health Research,s Health Researcher of the ...
Cached Medicine Technology:Huifeng Bio-Pharmaceutical Technology Announces New Senior Vice President of Finance 2Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine 2
(Date:12/26/2014)... India Network Foundation, a non-profit US based sponsor ... a new version of “ EasySelect ”, a software ... for their visiting parents. The technology tool is designed ... when choosing an insurance plan by showing the benefits ... clicks. Many elderly Asian Indian parents often find it ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the ... the company announces big discounts on its bamboo ... , BambooFlooringChina.com is the world’s leader in bamboo flooring. ... until Jan. 20, 2015. , The bamboo mats are ... natural thread. All the bamboo strips for the mats ...
(Date:12/25/2014)... 2014 (HealthDay News) -- The risk of burns from ... you need to be extra cautious, an expert says. ... a significant increase in patients coming in with burns," ... County Volunteer Firefighters Burn Center of Stony Brook University ... full of joy, but if not careful, could quickly ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2
... HealthDay Reporter , SUNDAY, Sept. 19 (HealthDay News) ... standard inhaled steroids, the addition of Spiriva -- a medication ... a new study finds. However, the study authors and ... much longer, larger clinical trials are needed. Tiotropium bromide ...
... of Utah determined that the 2009 pandemic influenza A ... children than the seasonal flu. The most common ... of the study, the most extensive evaluation of neurological ... the September issue of Annals of Neurology , ...
... researchers has identified four chromosome locations with genetic changes ... developing ovarian cancer. The findings appear in Nature ... Clinic researcher. Researchers say that while more needs ... chromosomal regions involved in susceptibility, the discoveries move them ...
... researchers have discovered how HIV-1, the virus that causes AIDS, ... , The scientists, who report their findings in Nature ... understand how important anti-AIDS treatments can fail and could help ... "What we,ve found is the detailed way in which the ...
... help surgeons more accurately locate breast cancers, reduce the ... patients. Microscopic gas-filled spheres of silica, a porous glass, ... their position using ultrasound imaging in the operating room. ... at the University of California, San Diego, created the ...
... HealthDay Reporter , FRIDAY, Sept. 17 (HealthDay News) -- ... father are likely to reach puberty earlier than others, ... absence predicted earlier puberty, but it did not in ... "Girls in upper-income households without a father were at ...
Cached Medicine News:Health News:Early Trial Suggests COPD Drug Might Help Some Asthmatics 2Health News:Early Trial Suggests COPD Drug Might Help Some Asthmatics 3Health News:Higher incidence of seizures seen in children with H1N1 virus compared to seasonal flu 2Health News:Better marker for breast cancer may reduce need for second surgeries 2Health News:Absent Father Might Mean Earlier Puberty for Higher-Income Girls 2Health News:Absent Father Might Mean Earlier Puberty for Higher-Income Girls 3
... complete line of flowmeters, available in oxygen, air, heliox ... a variety of calibrations to best suit your application. ... gas in use, the Amvex Flowmeter is a user ... with I. For Power Take-Off add PT to the ...
0-3.5 LPM Oxygen Flowmeter with Chemetronmale inlet...
0-15 LPM Oxygen Flowmeter with Ohmeda male inlet...
(1/2-8 LPM), 50 psi, 1/ 8" NPT female back inlet...
Medicine Products: